Trial Details

Authorised
Basic Information
Clinical ID c5149
Identifier EUCTR2004-004325-10-GB
Trial Title Evaluate Whether A Short Course Of Once Weekly Risedronate Prevents Bone Loss Following High-Dose Steroid Therapy For An Acute Exacerbation Of Inflammatory Bowel Disease. - Residronate prevening bone loss in IBD during short course steroids.
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions We aim to determine whether Risedronate is effective at preventing acute bone loss associated with a short course of corticosteroid (CS) therapy to treat exacerbations of inflammatory bowel disease (IBD).
Interventions Trade Name: Actonel Once a Week 35mgPharmaceutical Form: Pharmaceutical form of the placebo: Capsule*Route of administration of the placebo: Oral useTrade Name: CACIT D3 effervescent granules, 500 mg/440 IUPharmaceutical Form:
Participant Information
Sponsor United Bristol Healthcare Trust
City NULL
Country/Region United Kingdom
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement NULL
Study Design
Study Type Interventional clinical trial of medicinal product
Phase NULL
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL